Pharma brands achieved the most impressions from ABC and saw a year-over-year increase in impressions from cable channels like Fox News, CNN and MSNBC.

Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...

The FDA has accepted the resubmission of a BLA for odronextamab for the treatment of patients with relapsed/refractory ...

The FDA has accepted the sNDA and set an action goal date of March 23, 2025, under the Prescription Drug User Fee Act ... Alnylam's partner, Regeneron Pharmaceuticals, reported positive updated ...

Kennedy Jr. Trump's pick has been a vocal critic of mainstay health care companies, especially in the prescription drug and immunization ... like Eli Lilly and Regeneron Pharmaceuticals Inc ...

However, the company expects an adverse revenue impact of $1.1 billion in 2025 due to Medicare's prescription drug plan changes ... Meanwhile, JPMorgan categorized Regeneron (REGN) and Merck ...

8,9 NT-501 is under review by the FDA, with a Prescription Drug User Fee Act date of March 18 ... Genentech, Iveric Bio, Regeneron, REGENXBIO, and ZEISS. Singh reports having received research grants ...

It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

Regeneron Pharmaceuticals (NASDAQ:REGN) is one of the leaders in the ophthalmic disease therapeutics market. In this article, dear Seeking Alpha readers, I present five factors that explain why I ...

Long Island's six Regeneron Science Talent Search finalists are not yet out of high school and already, they've worked in some of the country's leading laboratories, helped to advance scientific ...

A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results that could allow the company to seek regulatory approval for the one ...